<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372307</url>
  </required_header>
  <id_info>
    <org_study_id>2003/275</org_study_id>
    <nct_id>NCT00372307</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris</brief_title>
  <official_title>Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months.
      After a baseline visit, patient returns for a control visit after 3 and 6 months of
      treatment. One reference lesion is clinically evaluated with pictures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repigmentation percentage of the reference lesion after 6 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with repigmentation after 3 and 6 months.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repigmentation percentage of the reference lesion after 3 months.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (month 3 and 6).</measure>
  </secondary_outcome>
  <enrollment>26</enrollment>
  <condition>Vitiligo Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Application of pimecrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active or stable vitiligo vulgaris

          -  lesions at head or neck + maximum 10% lesions at the rest of the body

        Exclusion Criteria:

          -  Topica during last 2 weeks

          -  Photo(chemo)therapy during last 4 weeks

          -  Segmentary vitiligo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marie Naeyaert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <reference>
    <citation>Boone B, Ongenae K, Van Geel N, Vernijns S, De Keyser S, Naeyaert JM. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol. 2007 Jan-Feb;17(1):55-61. Epub 2007 Feb 27. Review.</citation>
    <PMID>17324829</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2006</study_first_submitted>
  <study_first_submitted_qc>September 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2006</study_first_posted>
  <last_update_submitted>December 19, 2007</last_update_submitted>
  <last_update_submitted_qc>December 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

